InMed Pharmaceuticals Inc (INM)

[rosie10]

InMed Receives Exemption Status from Health Canada
Mar 23, 2015, 08:00 ET from InMed Pharmaceuticals Inc.

VANCOUVER, British Columbia, March 23, 2015 /PRNewswire/-- InMed Pharmaceuticals Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced that it has received a notice from Health Canada dated March 12, 2014, approving InMed's application for an exemption under Section 56 of the Controlled Drugs and Substances Act.

This exemption allows InMed to use a specified quantity of selected Cannabinoid compounds including Delta 9-Tetrahydrocannabinol and Cannabidiol. Importantly this exemption allows InMed to possess the controlled substance and to administer them for Research & Development purposes which include; in vitro studies as well as the use of these compounds in animal models of human diseases.

Craig Schneider, President & CEO states, "Obtaining this exemption is a critical milestone for InMed as we prepare for human clinical studies for our lead programs in Glaucoma (CTI-085) and Arthritis (CTI-091) moving towards the clinical development of their respective proprietary delivery systems".

The Office of Controlled Substance licensed dealers has also been notified so that it may import the controlled substances on behalf of InMed.

[url][/url][tag]insert-text-here[/tag]http://www.prnewswire.com/news-releases/inmed-receives-exemption-status-from-health-canada-300054169.html